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Introduction
Dense breast tissue increases the risk of breast cancer [1,2] and can mask breast cancer, thereby 
resulting in false-negative mammography examinations [3]. Recently, legislation has been passed 
in many states of the United States that requires direct notification to women of their breast 
density on screening mammography, and information on supplementary screening tools such as 
ultrasononography (US) or magnetic resonance imaging (MRI) for women with dense breasts [4]. 
Thus, after the enactment of this law, the number of supplementary screening US evaluations 
performed in women with mammographically dense breasts in the United States has increased [5-7]. 
This review presents the cancer yield and the clinico-pathological characteristics of cancer detected 
by screening US only, including those found through supplementary hand-held screening US and 
automated breast ultrasonography (ABUS) in various countries. 
Cancer Yield of Hand-Held US in Western Women at High Risk of 
Breast Cancer
In asymptomatic women, supplementary hand-held US performed by radiologists detected 1.9-6.8 
additional cancers per 1,000 women [8-13]. In studies that included women at high risk of breast 
cancer, supplementary hand-held US identified 1.9 to 4.2 additional cancers per 1,000 women, and 
83% to 100% of the US-detected cancers were invasive [8,10-12]. The median or mean tumor 
size of the invasive cancers was 10 mm [8,12], and 73% of the 15 invasive cancers were less than 
10 mm in size [10]. About 89% to 97.3% of the invasive cancers were node-negative [8,12]. In a 
study that had screening mammography and US performed in a randomized order and that included 
women with dense breasts and with at least one high risk factor for breast cancer, supplementary 
US identified 12 additional cancers (4.2 additional cancers per 1,000 women) [8]. Only one of these 
12 cancers (8.3%) was Breast Imaging Reporting and Data System (BI-RADS) category 5 on the 
supplementary US; 11 (91.6%) were invasive, and 89% (8 of 9 with staging) were node-negative 
[8]. In a large series study by Girardi et al. [12], 22,313 women with negative mammography were 
included and 9.8% of these women had a personal history of breast cancer. Forty-one cancers were 
identified on the supplementary US; thus, supplementary US identified 1.9 cancers per 1,000 women 
[12]. Of these 41 cancers, 37 (90%) were invasive cancer and 36 (97.3%) were node-negative [12]. 
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In women with a personal history of breast cancer, more cancers 
were found: 5.5 cancers per 1,000 women compared with 1.5 
cancers in women without a personal history of breast cancer [12]. 
In a study by De Felice et al. [11], women without suspicious lesions 
(categories 4 and 5) on mammography underwent supplementary 
US. Supplementary US detected 6.8 cancers per 1,000 women, 
higher than in the other studies because of the different study 
population [11].
Cancer Yield of Hand-Held US in Asian Women 
at Average Risk of Breast Cancer
In women at average risk of breast cancer, supplementary screening 
US can also identify breast cancer [9,13]. In two studies that 
included Asian women at average risk of breast cancer and negative 
or benign mammography results and that excluded women with a 
familial or personal history of breast or ovarian cancer, with chest 
irradiation, and with a BRCA mutation, supplementary hand-held 
screening US by radiologists identified 2 to 3.3 additional cancers 
per 1,000 women [9,13]. In a study by Moon et al. [13], four 
cancers in 2,005 women were found and were assessed as BI-RADS 
category 4 or 3 on the supplementary US. Additional 1.8 cancers per 
1,000 women were found in women with dense breasts who also 
underwent supplementary screening US more frequently, whereas 
2.9 cancers were found in women with fatty breasts [13]. In a study 
by Chang et al. [9], all five cancers were found in women with 
heterogeneously or extremely dense breasts. Of the supplementary 
US-detected cancers in Asian women at average risk of breast 
cancer, only 50% to 60% of cancers were invasive cancer [9,13], 
which was lower than the invasive cancer frequency of 83.3% to 
91.7% found in studies performed in Western countries, which 
included women at high risk of breast cancer [8,12]. This difference 
may be attributed to the inclusion of women at average risk of 
breast cancer rather than to any difference in ethnicity [9,13]. 
Prevalence Versus Incidence Screening
Prevalence screening is defined as the first round of screening 
using a screening tool, and incidence screening is defined as the 
subsequent round of screening. Prevalence screening with US can 
detect more cases of breast cancer and more advanced breast 
cancer cases than incidence screening [7]. One point of interest is 
whether or not even incidence screening with US can detect small 
invasive node-negative cancer. To define the detection benefit of 
supplementary screening US on incidence screening, the clinical 
and pathological characteristics between the cancers detected on 
prevalence and incidence screening US should be compared in the 
same study population. Berg et al. [14] reported the results of three 
rounds of screening US in the same study population. In the second 
and third rounds, 20 cancers were found on the supplementary 
US; thus, 3.7 additional cancers per 1,000 women per year were 
identified [14]. In each subsequent round, the detection rate of 3.7 
cancers per 1,000 women was lower than 4.2 cancers per 1,000 
women detected on prevalence screening [8,14]. Of the 20 cancers 
on the supplementary US, 19 (95%) were invasive cancer. Thus, 
upon incidence screening, US could identify additional cancers, 
particularly invasive cancer, although the cancer yield decreased. 
Supplementary Screening US in the State of 
Connecticut in the United States
Connecticut was the first state to pass legislation requiring direct 
notification to women of their breast density and supplementary 
screening tests, and the first state to require insurance companies 
to cover supplementary screening US [4-7]. Thus, Connecticut is 
the ideal place to assess the potential of supplementary screening 
US to detect mammographically occult breast cancer in women 
with dense breasts [6]. After the legislation was passed, Hooley 
et al. [4] retrospectively investigated the cancer yield and the 
characteristics of supplementary US-detected cancers in women 
with dense breasts for 1 year. Supplementary US examinations were 
performed by technologists. Three cases of cancer were identified 
by supplementary US, and the overall cancer yield was 3.2 cancers 
per 1,000 women. Two of the three cancers (66.7%) were invasive 
cancers, which were 9 mm and 5 mm in size. All invasive cancers 
were node-negative. After the new law was passed, supplementary 
screening US performed by technologists could identify additional 
cancers in women with dense breasts. These results from 
technologists were comparable with the cancer detection rates by 
radiologists [8,9,11-15]. 
To ascertain whether the implementation of a formal screening 
program in Connecticut affected the cancer yield of supplementary 
screening breast US, data after and prior to the passage of the law 
were compared [5]. Supplementary US examinations were performed 
by technologists. After the new legislation was introduced, women 
with older age, menopause, and dense breasts, and those without a 
family history of breast cancer underwent supplementary screening 
US more frequently [5]. In the pre-law group, supplementary 
screening US did not detect any malignancy [5]. In the post-law 
group, 10 cancers were found on supplementary screening US; thus, 
1.8 cancers per 1,000 women were identified [5]. All 10 cancers 
were invasive cancers with a mean size of 9.7 mm, and 77.8% (7 of 
9 with staging) were node-negative [5]. 
To ascertain the detection benefit of continuing annual US 
Screening detected cancers
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screening after a formal screening program, the cancer detection 
rates of the first and the second year after the enactment of the new 
law were investigated using multicenter data [6,7]. In the first year, 
28 cancers among 8,647 women were found on supplementary US; 
thus, supplementary US identified 3.2 cancers per 1,000 women [6]. 
In the second year, 24 cancers among 10,282 women were found; 
thus, 2.3 cancers per 1,000 women were found on supplementary 
US [7]. Although more women underwent supplementary screening 
US in the second year, the cancer detection rates were comparable 
[6,7]. Thus, in practice, supplementary screening US performed in 
both the first and the second year after the enactment of the new 
law was able to detect additional cancers.
Automated Breast US
Supplementary hand-held US examinations are performed by 
radiologists or technologists, are labor-intensive and operator-
dependent, and are not standardized for acquisition and recording 
images. The number of supplementary screening US examinations 
performed continuously increased after the Connecticut legislation 
was passed [5-7]. ABUS can standardize imaging acquisition and 
recording and can separate the performance and interpretation 
of US examinations [16]. Kelly et al. [17] evaluated the cancer 
detection rate of ABUS (SonoCine, Reno, NV, USA). Among 6,425 
examinations of mammography and ABUS, 23 cancers were 
found on supplementary ABUS only; thus, 3.6 cancers per 1,000 
examinations were identified [17]. Of the 23 cancers, 17 (73.9%) 
were invasive cancer and 15 (88.2%) were less than 20 mm in size. 
In another study using three-dimensional ABUS (Somo V, U-Systems, 
Sunnyvale, CA, USA), 15318 asymptomatic women 25 years old 
or older with heterogeneously or extremely dense breasts were 
included [18]. Thirty cancers were detected on supplementary ABUS; 
thus, supplementary ABUS identified two cancers per 1,000 women 
[18]. Twenty-eight of 30 cancers (93.3%) were invasive, and the 
mean lesion size was 12.9 mm [18]. Of the 27 invasive cancers 
with staging, 25 (92.6%) were node-negative [18]. Supplementary 
ABUS can detect small invasive node-negative cancers. The cancer 
yield, the detected cancer size, the frequency of invasive tumors, 
and the node status of supplementary ABUS are similar to those of 
supplementary hand-held US.
Mortality Reduction
The efficacy and effectiveness of supplementary screening US have 
been proven through many studies [4-10,12,13,17-19]. About 
50% to 100% of breast cancers identified by supplementary 
hand-held US or ABUS were small invasive node-negative cancers 
[4-10,12,13,17-19]. Thus, we assume that supplementary 
screening US can reduce mortality. However, a majority of women 
undergoing supplementary screening US are at average risk and no 
methodologically sound evidence for mortality reduction is available 
justifying the routine use of US as an adjunct screening tool in such 
a population [20]. The efficiency of supplementary screening US, that 
is, whether it is worth performing in daily practice, has not yet been 
proven. Problems related to high false-positive rates such as high 
short-term follow-up rates and high benign biopsy rates need to be 
solved along with issues of mortality reduction in order to achieve 
maximum efficiency.
Conclusion
No medical organization recommends supplementary screening 
US on the basis of breast density alone. The American College 
of Radiology and the Society of Breast Imaging recommends 
supplementary screening US only for women with a greater 
than 20% lifetime risk of developing breast cancer who cannot 
undergo MRI examinations. Currently, only legislation recommends 
supplementary screening US for every woman with dense breasts 
irrespective of the risk of breast cancer. In Korea, supplementary 
screening US examinations have been performed frequently in 
women with dense breasts. Clinicians and women need to first 
discuss breast density and individual risks of developing breast 
cancer, and then these women can decide whether or not to 
undergo supplementary screening US. A randomized controlled trial, 
although difficult, is needed.
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